【摘要】 目的:探讨原发性肝癌(PLC)三维适形放射治疗中血清转化生长因子β1的变化。方法:应用血清转化生长因子β1(TGF-β1)抗原含量测定法,对30例原发性肝癌患者三维适形放射治疗前、放疗中和结束的血清TGF-β1进行测量。结果:三维适形放射治疗前(0Gy)、中(28Gy～30Gy)和结束(56Gy～60Gy)时患者血清的TGF-β1为11.56±2.16μg/L、10.46±1.64μg/L、9.32±1.57μg/L,正常组血清的TGF-β1为8.35±1.19μg/L;PLC组病人放射治疗前TGF-β1与正常人比较有统计学差异(P<0.05),PLC组病人放射治疗前TGF-β1与放疗中(P<0.05)、放疗结束(P=0.000)比较有统计学差异,正常人TGF-β1与放疗中(P=0.000)、放疗结束(P=0.021)比较有统计学差异;PLC近期有效组放疗结束的TGF-β1为8.814±0.975μg/L,无效组放疗结束的TGF-β1为10.723±0.581μg/L。结论:三维适形放射治疗可以调节TGF-β1水平,使患者TGF-β1水平趋向正常;PLC近期有效组放疗结束的TGF-β1水平趋向正常人,无效组趋向PLC放疗前水平。更多还原

【Abstract】 Objective:To explore the change of serum TGF-β1 in patients with primary liver carcinoma(PLC) before,during and after the three-dimensional conformal radiation therapy(3DCRT).Methods:Thirty patients with PLC were examined for serum TGF-β1 before,during and after the 3DCRT by ELISA.Results:The serum levels of TGF-β1 before(0Gy),during(28~30Gy) and after(56~60Gy) the 3DCRT were 11.56±2.16μg/L,10.46±1.64μg/L,9.32±1.57μg/L,respectively.The serum level of TGF-β1 in healthy group was 8.35±1.19μg/L.Compared with the healthy group,TGF-β1 in elevated in PLC group.In PLC group,there was a statistic difference in the serum contents of TGF-β1 before,during and after the 3DCRT.By the end of the therapy,the serum level of TGF-β1 in respond patients was 8.814±0.975μg/L,in non-respond patients was 10.723±0.581μg/L.Conclusion:3DCRT regulated the serum TGF-β1.The serum TGF-β1 trended to normal level in the PLC group after 3DCRT:in respond group,tend to the level of healthy group;in non-responded subgroup,tend to the level before 3DCRT.更多还原